SPRO
Price
$2.94
Change
+$0.04 (+1.38%)
Updated
Jun 27 closing price
Capitalization
164.38M
38 days until earnings call
SYRE
Price
$15.22
Change
-$0.80 (-4.99%)
Updated
Jun 27 closing price
Capitalization
918.58M
31 days until earnings call
Interact to see
Advertisement

SPRO vs SYRE

Header iconSPRO vs SYRE Comparison
Open Charts SPRO vs SYREBanner chart's image
Spero Therapeutics
Price$2.94
Change+$0.04 (+1.38%)
Volume$1.69M
Capitalization164.38M
Spyre Therapeutics
Price$15.22
Change-$0.80 (-4.99%)
Volume$2.21M
Capitalization918.58M
SPRO vs SYRE Comparison Chart in %
Loading...
SPRO
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
SYRE
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
SPRO vs. SYRE commentary
Jun 30, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is SPRO is a Buy and SYRE is a Buy.

Interact to see
Advertisement
COMPARISON
Comparison
Jun 30, 2025
Stock price -- (SPRO: $2.94 vs. SYRE: $15.22)
Brand notoriety: SPRO and SYRE are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: SPRO: 30% vs. SYRE: 393%
Market capitalization -- SPRO: $164.38M vs. SYRE: $918.58M
SPRO [@Biotechnology] is valued at $164.38M. SYRE’s [@Biotechnology] market capitalization is $918.58M. The market cap for tickers in the [@Biotechnology] industry ranges from $304.6B to $0. The average market capitalization across the [@Biotechnology] industry is $2.32B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

SPRO’s FA Score shows that 1 FA rating(s) are green whileSYRE’s FA Score has 0 green FA rating(s).

  • SPRO’s FA Score: 1 green, 4 red.
  • SYRE’s FA Score: 0 green, 5 red.
According to our system of comparison, SPRO is a better buy in the long-term than SYRE.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

SPRO’s TA Score shows that 5 TA indicator(s) are bullish while SYRE’s TA Score has 5 bullish TA indicator(s).

  • SPRO’s TA Score: 5 bullish, 4 bearish.
  • SYRE’s TA Score: 5 bullish, 5 bearish.
According to our system of comparison, SPRO is a better buy in the short-term than SYRE.

Price Growth

SPRO (@Biotechnology) experienced а -2.65% price change this week, while SYRE (@Biotechnology) price change was +1.40% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was +4.13%. For the same industry, the average monthly price growth was +31.22%, and the average quarterly price growth was +12.91%.

Reported Earning Dates

SPRO is expected to report earnings on Aug 07, 2025.

SYRE is expected to report earnings on Jul 31, 2025.

Industries' Descriptions

@Biotechnology (+4.13% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
SYRE($919M) has a higher market cap than SPRO($164M). SPRO has higher P/E ratio than SYRE: SPRO (10.75) vs SYRE (1.68). SPRO YTD gains are higher at: 185.437 vs. SYRE (-34.622). SPRO has higher annual earnings (EBITDA): -73.06M vs. SYRE (-214.36M). SYRE has more cash in the bank: 565M vs. SPRO (48.9M). SYRE has less debt than SPRO: SYRE (0) vs SPRO (3.96M). SPRO has higher revenues than SYRE: SPRO (28.3M) vs SYRE (0).
SPROSYRESPRO / SYRE
Capitalization164M919M18%
EBITDA-73.06M-214.36M34%
Gain YTD185.437-34.622-536%
P/E Ratio10.751.68638%
Revenue28.3M0-
Total Cash48.9M565M9%
Total Debt3.96M0-
FUNDAMENTALS RATINGS
SPRO vs SYRE: Fundamental Ratings
SPRO
SYRE
OUTLOOK RATING
1..100
5050
VALUATION
overvalued / fair valued / undervalued
1..100
59
Fair valued
75
Overvalued
PROFIT vs RISK RATING
1..100
100100
SMR RATING
1..100
9898
PRICE GROWTH RATING
1..100
3464
P/E GROWTH RATING
1..100
584
SEASONALITY SCORE
1..100
n/an/a

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

SPRO's Valuation (59) in the Pharmaceuticals Major industry is in the same range as SYRE (75). This means that SPRO’s stock grew similarly to SYRE’s over the last 12 months.

SPRO's Profit vs Risk Rating (100) in the Pharmaceuticals Major industry is in the same range as SYRE (100). This means that SPRO’s stock grew similarly to SYRE’s over the last 12 months.

SPRO's SMR Rating (98) in the Pharmaceuticals Major industry is in the same range as SYRE (98). This means that SPRO’s stock grew similarly to SYRE’s over the last 12 months.

SPRO's Price Growth Rating (34) in the Pharmaceuticals Major industry is in the same range as SYRE (64). This means that SPRO’s stock grew similarly to SYRE’s over the last 12 months.

SPRO's P/E Growth Rating (5) in the Pharmaceuticals Major industry is significantly better than the same rating for SYRE (84). This means that SPRO’s stock grew significantly faster than SYRE’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
SPROSYRE
RSI
ODDS (%)
Bearish Trend 4 days ago
76%
Bearish Trend 4 days ago
88%
Stochastic
ODDS (%)
Bearish Trend 4 days ago
81%
Bullish Trend 4 days ago
89%
Momentum
ODDS (%)
N/A
Bearish Trend 4 days ago
89%
MACD
ODDS (%)
Bearish Trend 4 days ago
85%
Bearish Trend 4 days ago
86%
TrendWeek
ODDS (%)
Bearish Trend 4 days ago
89%
Bullish Trend 4 days ago
84%
TrendMonth
ODDS (%)
Bullish Trend 4 days ago
76%
Bullish Trend 4 days ago
84%
Advances
ODDS (%)
Bullish Trend 11 days ago
71%
Bullish Trend 21 days ago
84%
Declines
ODDS (%)
N/A
Bearish Trend 11 days ago
90%
BollingerBands
ODDS (%)
Bearish Trend 4 days ago
90%
Bearish Trend 4 days ago
90%
Aroon
ODDS (%)
Bullish Trend 4 days ago
80%
Bullish Trend 4 days ago
90%
View a ticker or compare two or three
Interact to see
Advertisement
SPRO
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
SYRE
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
OAYLX82.170.44
+0.54%
Oakmark Select Advisor
CCDVX18.870.10
+0.53%
Calamos Dividend Growth C
RYPCX6.82N/A
N/A
Royce Small-Cap Fund Consult
LMGAX27.45-0.02
-0.07%
Lord Abbett Growth Opportunities A
TSCGX17.46-0.03
-0.17%
Thrivent Small Cap Growth S

SPRO and

Correlation & Price change

A.I.dvisor indicates that over the last year, SPRO has been loosely correlated with ASBP. These tickers have moved in lockstep 62% of the time. This A.I.-generated data suggests there is some statistical probability that if SPRO jumps, then ASBP could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To SPRO
1D Price
Change %
SPRO100%
+1.38%
ASBP - SPRO
62%
Loosely correlated
-7.03%
CLGN - SPRO
43%
Loosely correlated
+0.36%
ITOS - SPRO
35%
Loosely correlated
-0.60%
XENE - SPRO
32%
Poorly correlated
+0.62%
SYRE - SPRO
31%
Poorly correlated
-4.99%
More

SYRE and

Correlation & Price change

A.I.dvisor indicates that over the last year, SYRE has been loosely correlated with CGON. These tickers have moved in lockstep 57% of the time. This A.I.-generated data suggests there is some statistical probability that if SYRE jumps, then CGON could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To SYRE
1D Price
Change %
SYRE100%
-4.99%
CGON - SYRE
57%
Loosely correlated
-0.46%
BEAM - SYRE
55%
Loosely correlated
-1.98%
IMNM - SYRE
54%
Loosely correlated
-0.23%
APGE - SYRE
53%
Loosely correlated
N/A
XNCR - SYRE
53%
Loosely correlated
-3.10%
More